CN105209034A - 用于利用藻类化合物的组合物和方法 - Google Patents
用于利用藻类化合物的组合物和方法 Download PDFInfo
- Publication number
- CN105209034A CN105209034A CN201480022992.6A CN201480022992A CN105209034A CN 105209034 A CN105209034 A CN 105209034A CN 201480022992 A CN201480022992 A CN 201480022992A CN 105209034 A CN105209034 A CN 105209034A
- Authority
- CN
- China
- Prior art keywords
- algae
- compositions
- acid
- poa
- epa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title description 2
- 239000002775 capsule Substances 0.000 claims abstract description 31
- 239000000047 product Substances 0.000 claims abstract description 28
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- 235000013361 beverage Nutrition 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 230000037147 athletic performance Effects 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 208000006011 Stroke Diseases 0.000 claims abstract description 6
- 239000013589 supplement Substances 0.000 claims abstract description 6
- 206010012289 Dementia Diseases 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 5
- 235000016709 nutrition Nutrition 0.000 claims abstract description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 176
- 241000195493 Cryptophyta Species 0.000 claims description 149
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 88
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 88
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 69
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 69
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 69
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 69
- 239000000194 fatty acid Substances 0.000 claims description 49
- 150000004665 fatty acids Chemical class 0.000 claims description 48
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 47
- 229930195729 fatty acid Natural products 0.000 claims description 47
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 30
- 235000021003 saturated fats Nutrition 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 22
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 20
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 15
- 125000004494 ethyl ester group Chemical group 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 10
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 10
- 229940114079 arachidonic acid Drugs 0.000 claims description 10
- 235000021342 arachidonic acid Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 9
- 150000001982 diacylglycerols Chemical class 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 150000002759 monoacylglycerols Chemical class 0.000 claims description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 8
- 102100032752 C-reactive protein Human genes 0.000 claims description 7
- 108010076365 Adiponectin Proteins 0.000 claims description 6
- 102000011690 Adiponectin Human genes 0.000 claims description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 102000016267 Leptin Human genes 0.000 claims description 6
- 108010092277 Leptin Proteins 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 6
- 229940039781 leptin Drugs 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 108010075254 C-Peptide Proteins 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 101800001586 Ghrelin Proteins 0.000 claims description 5
- 102400000442 Ghrelin-28 Human genes 0.000 claims description 5
- 102000051325 Glucagon Human genes 0.000 claims description 5
- 108060003199 Glucagon Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 5
- 229960004666 glucagon Drugs 0.000 claims description 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 229940100601 interleukin-6 Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims 6
- 125000003203 triacylglycerol group Chemical group 0.000 claims 4
- 230000002596 correlated effect Effects 0.000 claims 3
- 230000036186 satiety Effects 0.000 claims 3
- 235000019627 satiety Nutrition 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002028 Biomass Substances 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 229940127554 medical product Drugs 0.000 abstract description 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 16
- 125000001931 aliphatic group Chemical group 0.000 description 15
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 108091006374 cAMP receptor proteins Proteins 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 229960002969 oleic acid Drugs 0.000 description 3
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001661345 Moesziomyces antarcticus Species 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- -1 alkene acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000011872 anthropometric measurement Methods 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/16—Fatty acid esters
- A21D2/165—Triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
- C11C3/08—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with fatty acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1876—Long-chain fatty acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本文中提供了在抑制炎症的方法中利用POA、EPA、POA与EPA的共混物、总藻油组合物和/或全生物质组合物的示例性组合物、产品和胶囊剂,所述炎症包括心血管病、糖尿病、肥胖症、卒中、代谢综合征、痴呆、阿尔茨海默病和/或癌症中的炎症。所述示例性组合物、产品和胶囊剂可经口、表面、静脉内和/或皮下施用。本文中的示例性组合物可用作饲料、食品、食品补充剂、饮料、饮料补充剂、营养产品、用于运动表现的产品、药物产品和/或用于哺乳动物(包括人)使用的医疗产品。
Description
相关申请的交叉引用
本申请要求于2013年3月15日提交的标题为“(EPA)AlgalBiomassandOilCompositionsandImpactonHealth”的美国临时专利申请序列号61/800,114的权益和优先权,其在此通过引用并入。
本申请要求于2013年3月15日提交的标题为“MicroalgaSpeciesandIndustrialApplications”的美国临时专利申请序列号61/800,029的权益和优先权,其在此通过引用并入。
本申请涉及与本申请同时于2013年9月12日提交的标题为“AlgalOmega7Compositions”的美国非临时专利申请序列号14/025,766,其在此通过引用并入。
本申请涉及与本申请同时于2013年9月12日提交的标题为“AlgalOilCompositions”的美国非临时专利申请序列号14/025,762,其在此通过引用并入。
本申请涉及与本申请同时于2013年9月12日提交的标题为“ConversionofFreeFattyAcidstoEthylEsters”的美国非临时专利申请序列号14/025,740,其在此通过引用并入。
本申请涉及与本申请同时于2013年9月12日提交的标题为“AlgalOmega7andAlgalOmega3BlendCompositions”的美国非临时专利申请序列号14/025,756,其在此通过引用并入。
背景技术
技术领域
本发明涉及藻类生物化学,并且更具体地涉及藻类组合物以及利用方法。
发明概述
本文中提供了用于哺乳动物食用(consumption)的示例性产品,其选自以下任一种:含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(Eicosapentaenoiacid,EPA)的组合物;含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(palmitoleicacid,POA)和少于约10%藻类饱和脂肪酸的组合物;含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;含有按总重计至少20%藻类EPA、至少17%藻类POA、约0%至20%藻类饱和脂肪、少于约10%藻类ARA并且基本不含藻类DHA的总藻油组合物(totalalgaloilcomposition);含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%ARA并且基本不含藻类DHA且基本不含藻类饱和脂肪酸的总藻油组合物;或者含有至少约10%藻类脂质、至少约15%藻类碳水化合物、至少约25%藻类蛋白质、至少约3%水分和至少约5%灰分的藻类生物质组合物(algalbiomasscompsition)。示例性产品还可包括饲料产品、食物产品、食品补充剂、膳食产品、用于运动表现(athleticperformance)的组合物和/或产品、药物产品、营养产品、饮料产品或饮料补充剂产品。示例性产品可以是乙酯(ethylester,EE),单酰甘油、二酰甘油或三酰甘油(mono,di,ortriacylglycerol,MAG、DAG、TAG),磷脂(phospholipid,PL),半乳糖脂(galactolipid,GL),游离脂肪酸(freefattyacid,FFA)或硫代异鼠李糖二酰甘油(sulfoquinovosyldiacylglycerol,SQDG)的形式。
本文中还提供了用于抑制哺乳动物对象的组织的炎症的示例性方法,所述方法包括以有效剂量施用选自以下任一种的组合物:含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)的组合物;含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)和少于约10%藻类饱和脂肪酸的组合物;含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;含有按总重计至少20%藻类EPA、至少17%藻类POA、约0%至20%藻类饱和脂肪、少于约10%ARA并且基本不含藻类DHA的总藻油组合物;含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%ARA并且基本不合藻类DHA且基本不含藻类饱和脂肪酸的总藻油组合物。根据一些示例性方法,所述有效剂量约为20毫克/天至5克/天,和/或可包括施用所选组合物至少30天的治疗期和/或在施用的第一天测量炎症的临床标志(clinicalmarker)。根据一些示例性方法,临床标志可包括体重、甘油三酯水平、总胆固醇、低密度脂蛋白、高密度脂蛋白、C反应蛋白、脂连蛋白、脂肪酸、肿瘤坏死因子α、C肽、单核细胞趋化蛋白-1(monocytechemoattractantprotein-1)、胰岛素水平、生长素释放肽、瘦素或胰高血糖素中的任一种。示例性方法还可包括在第30天测量炎症的临床标志,其中临床标志测量指示相对于在第30天之前进行的临床标志测量有所改善。根据一些示例性方法,炎性疾病可包括心血管病、糖尿病、肥胖症、卒中、代谢综合征、痴呆、阿尔茨海默病(Alzheimer'sdisease)和/或癌症。
本文中提供了胶囊剂,其包含至少约50毫克选自以下的任一种:含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)的组合物;含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)和少于约10%藻类饱和脂肪酸的组合物;含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;和/或含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%藻类ARA并且基本不合藻类DHA且基本不合藻类饱和脂肪酸的总藻油组合物。根据一些示例性胶囊剂,所述胶囊剂可以是营养胶囊剂、医疗胶囊剂或药物胶囊剂。在又一些示例性胶囊剂中,所述胶囊剂可含有抗氧化剂。
本文中提供了用于在人中减轻慢性炎症和肥胖症相关体重的示例性方法,所述方法包括每天经口施用至少一颗胶囊剂,持续至少30天的治疗期,所述胶囊剂的至少其25%的胶囊容积包含组合物,所述组合物还含有按干重计约90%棕榈油酸、少于约0.5%饱和脂肪酸、少于约2%花生四烯酸、基本不含二十二碳六烯酸并且含有少于约10%二十碳五烯酸,其中所述组合物是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG),磷脂(PL),半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
附图简述
图1是用于抑制哺乳动物对象之组织的炎症的示例性方法的流程图。
发明详述
脂肪酸是具有长脂族尾(链)的羧酸,其是饱和或不饱和的。大多数天然脂肪酸的链具有偶数个(4至28个)碳原子。饱和脂肪酸在碳原子间无双键。不饱和脂肪酸在碳原子间具有一个或更多个双键。当在不饱和脂肪酸上从末端甲基碳开始向羰基碳计数时,第一个双键代表ω双键,例如在ω3、ω6或ω7脂肪酸中所观察到的。
棕榈油酸(POA)是具有一个双键的具有16-碳链的ω-7单不饱和脂肪酸,表示为C16:1n7。其是一种有益脂肪酸,已表明其抑制炎症。ω-7的膳食来源见于动物和植物来源中,包括沙棘浆果(seabuckthornberry)、澳洲坚果(macadamianut)、冷水性鱼类(coldwaterfish)和乳脂(dairyfat)。然而,这些来源不是POA的经浓缩和/或经纯化来源,并且通常含有饱和和多不饱和脂肪的混合脂肪酸谱。
棕榈酸(palmiticacid,PA)是具有16-碳链但无双键的饱和脂肪酸,表示为C16:0。认为,饱和脂肪(例如棕榈酸)的食用提高发生炎症和/或炎性相关健康问题(包括糖尿病、肥胖症、卒中和心血管病)的风险。
α亚麻酸(alphalinolenicacid,ALA)是具有18-碳链和3个顺式双键的ω-3多不饱和脂肪酸(polyunsaturatedfattyacid,PUFA)。第一个双键位于脂肪酸链从甲基端开始的第三个碳原子,表示为C18:3n3。
油酸(oleicacid,OA)是具有一个双键的具有18-碳链的ω-9单不饱和脂肪酸,表示为C18:1n9。OA是橄榄油、澳洲坚果油及其他单不饱和脂肪的主要组分。
花生四烯酸(arachidonicacid,ARA)是具有20-碳链和4个顺式双键的ω-6PUFA;第一个双键位于从ω端开始的第6个碳。ARA也表示为C20:4n6。ω-6PUFA的膳食来源的实例包括精炼植物油(例如玉米油和大豆油)、种子和坚果以及从其提取的油。因此,食用在日常饮食中就已足够。
二十碳五烯酸(EPA)是具有以下含义C20:5n3的ω-3脂肪酸PUFA。其是具有20-碳链和5个顺式双键的羧酸;第一个双键位于从ω端开始的第3个碳。
二十二碳六烯酸(docosahexaenoicacid,DHA)是ω-3脂肪酸PUFA。其是具有22-碳链和6个顺式双键的羧酸;第一个双键位于从ω端开始的第3个碳。DHA也表示为C22:6n3。
另外,本文中提供的多种藻类组合物还可以是乙酯形式。这样的乙酯通过使游离脂肪酸与乙醇反应获得。称为酯化,所得乙酯允许在较低温度下对长链脂肪酸进行分馏(浓缩)。这一步骤允许将脂肪酸选择性地浓缩至高于天然所见的水平。
本文中提供的多种示例性藻类组合物的乙酯形式可如下被转化成甘油三酯形式:在甘油存在下与乙酯形式进行酶促反应,在真空下加热并将酶滤出。根据一些示例性方法,固定化脂肪酶(例如从南极洲假丝酵母(CandidaAntarctica)分离的那些)可从诸如Novozyme或SigmaAldrich的公司商购。
本文中的示例性组合物可包括含有按干重计大致约0.5%至大致约99%C16:1n7棕榈油酸(POA)的藻类脂肪酸组合物。这样的藻类组合还可含有(独立地或者以任意组合)按干重计:大致约0%至大致约99%饱和脂肪酸;大致约0%至大致约99%花生四烯酸;大致约0%至约99%二十二碳六烯酸;和/或大致约0%至大致约99%二十碳五烯酸。
本文中的示例性组合物可包括含有按干重计大致约0.5%至大致约99%C16:1n7棕榈油酸(POA)的藻类脂肪酸组合物。这样的藻类组合物还可含有(独立地或者以任意组合)按干重计:大致约0%至大致约10%饱和脂肪酸;大致约0%至大致约2%花生四烯酸;基本不含(即少于约0.5%)二十二碳六烯酸;和/或大致约0%至大致约10%二十碳五烯酸。
本文中的示例性组合物可包括这样的藻类脂肪酸组合物,其具有:按干重计大致约90%棕榈油酸、少于大致约10%饱和脂肪酸、少于大致约2%花生四烯酸、基本不含二十二碳六烯酸以及少于大致约10%5十碳五烯酸。
本文中的示例性组合物可包括含有按干重计至少约50%C16:1n7棕榈油酸和少于约10%饱和脂肪酸的藻类组合物。
本文中的示例性组合物可包括含有按总重计约0%至99%EPA以及以下一种或更多种的总藻油组合物:约0%至99%POA、少于约20%饱和脂肪(包括0%饱和脂肪或基本不含饱和脂肪)、约0%至99%ARA和/或约0%至99%DHA。根据另一些示例性的总藻油组合物,饱和脂肪可含有PA。
本文中的示例性组合物可包括含有按总重计约0%至99%OA以及不合以下物质或者含有以下一种或更多种的总藻油组合物:约0%至99%EPA、约0%至99%POA、少于约20%饱和脂肪(包括0%饱和脂肪或基本不含饱和脂肪)、约0%至99%ARA和/或约0%至99%DHA。根据另一些示例性的总藻油组合物,饱和脂肪可含有PA。
本文中的示例性组合物可包括含有按总重计至少20%EPA以及以下一种或更多种的总藻油组合物:至少17%POA、至少13%PA、至少约10%ARA和/或基本不含DHA。
本文中的示例性组合物可包括含有按总重计至少约30%EPA以及以下一种或更多种的总藻油组合物:至少约27%POA、至少约23%PA、少于约10%ARA和/或基本不含DHA。
本文中的示例性组合物可包括含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)和约0.5%至约99%C16:1n7棕榈油酸(POA)的藻类脂肪酸组合物。另一些示例性藻类脂肪酸组合物可含有(除上述物质之外)按干重计以下一种或更多种:约0%至99%花生四烯酸;约0%至99%二十二碳六烯酸;和/或少于约20%饱和脂肪酸(包括0%饱和脂肪酸或基本不含饱和脂肪)。根据另一些示例性总藻油组合物,饱和脂肪可含有PA。另一些示例性的富含饱和脂肪酰基部分的藻类组合物可以是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG),磷脂(PL),半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
本文中的示例性组合物可包括含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)和约0.5%至约99%C16:1n7棕榈油酸(POA)的藻类脂肪酸组合物。另一些示例性藻类脂肪酸组合物可含有按干重计以下一种或更多种:少于约5%花生四烯酸;基本不含二十二碳六烯酸;和/或少于约10%饱和脂肪酸。另一些示例性的富含饱和脂肪酰基部分的藻类组合物可以是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG)、磷脂(PL)、半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
本文中的示例性组合物可包括含有按干重计约0.5%至约99%C18:1n9油酸(OA)以及不含、含有以下一种或两种的藻类脂肪酸组合物:0.5%至约99%C20:5n3二十碳五烯酸(EPA)和约0.5%至约99%C16:1n7棕榈油酸(POA)。另一些示例性藻类脂肪酸组合物可含有(除上述物质之外)按干重计以下一种或更多种:约0%至99%花生四烯酸;约0%至99%二十二碳六烯酸;和/或少于约20%饱和脂肪酸(包括0%饱和脂肪酸或基本不合饱和脂肪)。根据另一些示例性总藻油组合物,饱和脂肪可含有PA。另一些示例性的富含饱和脂肪酰基部分的藻类组合物可以是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG),磷脂(PL),半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
本文中的示例性组合物可包括含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)的脂肪酸组合物。
本文中的示例性组合物可包括含有以下的全藻类生物质组合物:至少约10%脂质、至少约15%碳水化合物、至少约25%蛋白质、至少约3%水分和至少约5%灰分。
本文中的示例性组合物可用作饲料、食品、食品补充剂、饮料、饮料补充剂、营养产品、美容产品、化妆品、用于体重管理的产品、饱腹产品、用于运动表现的产品、药物产品和/或用于哺乳动物使用(包括人)的医疗产品。
本文中的示例性组合物可经口、表面(topically)、静脉内、和/或皮下施用。
本文中的示例性组合物可用于通过表面或经口施用来抑制哺乳动物对象的组织的炎症。根据一些示例性方法,多种示例性组合物可以以约1毫克/天至100克/天施用,持续1天至至多1年或更久的时间。另外,示例性的治疗方法可包括定期测量炎症的临床标志。在又一些示例性治疗方法中,哺乳动物对象可患有炎性疾病,包括心血管病、糖尿病、肥胖症、卒中、代谢综合征、痴呆、阿尔茨海默病或癌症。
本文中的一些或全部示例性组合物均可以是胶囊剂的形式:
1.具有宽范围的胶囊剂容积;
2.具有宽范围的内容物,1毫克至500克本文中的多种示例性组合物;和/或
3.具有宽范围的由本文中的多种示例性组合物填充的胶囊剂容积百分比。例如特定胶囊剂的至少约10%至约90%或更高的容积可被本文中多种示例性组合物中的一种或更多种填充。
含有全生物质(wholebiomass)的一些示例性胶囊剂可具有至少约500mg的内容物,含有EPA的一些示例性胶囊剂可具有至少约50mg的内容物。
本文中的一些或全部示例性组合物可不含或者基本不含(例如,约少于0.5%)DHA并含有低(例如,约0%至5%)ARA。
本文中的一些或全部示例性组合物可含有一定范围(例如,约0%至99%)的饱和脂肪。
本文中的一些或全部示例性总藻油组合物可具有少于约10%ARA。
本文中的一些或全部示例性全生物质组合物可具有至少约3%水分和至少约5%灰分。
图1是用于抑制哺乳动物对象之组织的炎症的示例性方法的流程图。
在步骤10,施用有效剂量的选自以下任一种的组合物:
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)和少于约10%藻类饱和脂肪酸的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;或者
含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%ARA并且基本不含藻类DHA且基本不含藻类饱和脂肪酸的总藻油组合物。
根据一些示例性方法,有效剂量约为20毫克/天至5克/天。根据多种示例性方法,POA的有效剂量可以为约1克/天至3克/天,并且可高达约5克/天或更高。根据另一些示例性方法,EPA的有效剂量可高达约3克/天。在又一些示例性方法中,有效剂量可基于其他因素,例如对象的年龄、性别和/或体重。
在步骤20,将所选组合物施用至少30天的治疗期。
在步骤30,可在施用的第一天测量炎症的临床标志。
根据一些示例性方法,临床标志是体重、甘油三酯水平、总胆固醇、低密度脂蛋白、高密度脂蛋白、C反应蛋白、脂连蛋白、脂肪酸、肿瘤坏死因子α、C肽、白介素-6、单核细胞趋化蛋白-1、胰岛素水平、生长素释放肽、瘦素或胰高血糖素中的任一种。
在步骤40,可在第30天测量炎症的临床标志。
根据大多数示例性方法,临床标志测量指示相对于在第30天之前进行的临床标志测量有所改善。在又一些示例性方法中,哺乳动物对象可以是人并且可患有炎性疾病,所述炎性疾病包括心血管病、糖尿病、肥胖症、卒中、代谢综合征、痴呆、阿尔茨海默病和/或癌症。
实施例1:炎症。
受试者群:患有或未患冠状动脉病的男性和女性。
合格:饮食稳定、高甘油三酯水平(空腹甘油三酯水平≥200mg/dl且≤2,000mg/dl)和/或高总胆固醇(≥6.5mmol/L)。
终点测量:体重、甘油三酯水平(“TG”)、低密度脂蛋白(“LDL”)、高密度脂蛋白(“HDL”)、总胆固醇(“TC”)、C反应蛋白(“CRP”)、脂连蛋白和脂肪酸。
研究设计:双盲的随机化安慰剂对照试验。
包含降脂剂,并且在研究期间不添加/改变药物。
对照组:仅饮食(基于美国心脏病协会(AmericanHeartAssociation,“AHA”指导方针))。
活动组:饮食+POA(POA可以为500毫克/天、1克/天或3克/天)。
POA=经高度纯化(>80%)的POA。
清洗,1m→导入期(限定脂质谱)→合格的受试者进入双盲RCT,3m→洗出,3m。
预期结果:炎症的标志有所改善。
例如,脂连蛋白提高,并且血清POA提高,CRP、TG、TC、LDL-C、血清PA、HDL-C降低。
实施例2:面包。
对于每天食用250mgPOA,面包提供推荐的250mgPOA需求的10%至20%,利用60%TG形式的POA产品,其中两种份量大小如下所示:
实施例3:饮料。
具有375g冰沙(smothie)的12流体盎司瓶(fluidouncebottle)。
实施例4:饲料。
实施例5:胶囊剂。
具有约993毫克以下成分的1000毫克胶囊剂:
880mg/g棕榈油酸-EE(88%)
50mg/g饱和脂肪(5%)
25mg/g棕榈酸
3mg/gω-6
2mgARA
40mg/gω-3(4%)
12mg/gEPA
4mg/gALA
0mg/gDHA
可能含有少于约20mg(2%)的α生育酚(维生素E)或其他抗氧化剂。
实施例6:膳食内分泌研究。
三种示例性组合物,包括:
1.含有按干重计至少约50%C16:1n7棕榈油酸和少于约10%饱和脂肪酸的藻类组合物;
2.含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)和约0.5%至约99%C16:1n7棕榈油酸(POA)的藻类脂肪酸组合物,并且更特别地;和/或
3.含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)的藻类脂肪酸组合物。
可将这些示例性组合物以约50mg/kg/体重至5000mg/kg/体重的不同剂量施用于大鼠,持续12周。每周可确定以下参数(包括给药之前):
1.体重,BMI,和人体测量(anthropometricmeasurement);
2.食物和水消耗;
3.血糖水平;
4.糖尿病标志,包括胰岛素、生长素释放肽、瘦素和胰高血糖素;
5.炎性标志:包括C肽、肿瘤坏死因子α和MCP-1;以及
6.脂肪酸谱(fattyacidprofile)。
可在经处理的和未经处理的大鼠之间进行炎性生物标志与糖尿病生物标志间的比较。预期,经处理大鼠的炎性和糖尿病症状将显著减轻,如上述指定参数的相应变化所证明的。
实施例7:膳食运动研究。
三种示例性组合物,包括:
1.含有按干重计至少约50%C16:1n7棕榈油酸和少于约10%饱和脂肪酸的藻类组合物;
2.含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)和约0.5%至约99%C16:1n7棕榈油酸(POA)的藻类脂肪酸组合物;和/或
3.含有按干重计约0.5%至约99%C20:5n3二十碳五烯酸(EPA)的藻类脂肪酸组合物。
可将这些示例性组合物以约50mg/kg/体重至5000mg/kg/体重的不同剂量施用于包括瘦大鼠和肥胖大鼠的多个组的大鼠,持续12周。运动方案在大鼠组间可有所不同。每周可确定以下参数(包括给药之前):
1.体重,BMI,和人体测量;
2.食物和水消耗;
3.血糖水平;
4.糖尿病标志,包括胰岛素、生长素释放肽、瘦素和胰高血糖素;
5.炎性标志:包括C肽、肿瘤坏死因子α、CRP、MCP-1和脂连蛋白;
6.脂肪酸/脂质谱,包括FFA、LDL、HDL、胆固醇;
7.ω3指数;以及
8.乳酸盐。
可在经处理的、未经处理的和静止大鼠之间进行炎性生物标志和运动表现生物标志间的比较。预期经处理大鼠的炎性和糖尿病症状将显著减轻,如上述指定参数的相应变化所证明的。
尽管上文已对多种实施方案进行了描述,但是应当理解,这些实施方案仅作为实例示出,并非限制。因此,优选实施方案的宽度和范围不应受上述任一示例性实施方案的限制。
Claims (30)
1.用于哺乳动物食用的产品,其选自以下任一种:
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)和少于约10%藻类饱和脂肪酸的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;
含有按总重计至少20%藻类EPA、至少17%藻类POA、约0%至20%藻类饱和脂肪、少于约10%藻类ARA并且基本不含藻类DHA的总藻油组合物;
含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%藻类ARA并且基本不含藻类DHA且基本不含藻类饱和脂肪酸的总藻油组合物;或者
含有至少约10%藻类脂质、至少约15%藻类碳水化合物、至少约25%藻类蛋白质、至少约3%水分和至少约5%灰分的藻类生物质组合物。
2.权利要求1所述选择的产品,其中所述产品是饲料产品、食物产品、食品补充剂、用于运动表现的产品、用于运动表现的补充剂、营养产品、饮料产品或饮料补充剂产品中的任一种。
3.权利要求2所述的食物产品,其是三酰甘油形式。
4.权利要求2所述的食品补充剂,其是三酰甘油形式。
5.权利要求2所述的饮料产品,其是三酰甘油形式。
6.权利要求2所述的饮料补充剂,其是三酰甘油形式。
7.权利要求1所述选择的产品,其中所述组合物是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG),磷脂(PL),半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
8.用于抑制哺乳动物对象之组织的炎症的方法,所述方法包括以有效剂量施用选自以下任一种的组合物:
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)和少于约10%藻类饱和脂肪酸的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;
含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%藻类ARA并且基本不含藻类DHA且基本不含藻类饱和脂肪酸的总藻油组合物;或者
含有按总重计至少20%藻类EPA、至少17%藻类POA、约0%至约20%藻类饱和脂肪、少于约10%藻类ARA并且基本不含藻类DHA的总藻油组合物。
9.权利要求8所述的方法,其中所述有效剂量约为20毫克/天至5克/天。
10.权利要求9所述的方法,其还包括施用所选择的组合物至少30天的治疗期。
11.权利要求10所述的方法,其还包括在施用的第一天测量炎症的临床标志。
12.权利要求11所述的方法,其中所述临床标志是体重、甘油三酯水平、总胆固醇、低密度脂蛋白、高密度脂蛋白、C反应蛋白、脂连蛋白、脂肪酸、肿瘤坏死因子α、C肽、单核细胞趋化蛋白-1、胰岛素水平、生长素释放肽、瘦素、IL-6(白介素-6)或胰高血糖素中的任一种。
13.权利要求10所述的方法,其还包括在第30天测量炎症的所述临床标志。
14.权利要求13所述的方法,其中所述临床标志测量指示相对于在第30天之前进行的临床标志测量有所改善。
15.权利要求8所述的方法,其还包括患有炎性疾病的哺乳动物对象。
16.权利要求15所述的方法,其中所述炎性疾病是心血管病、糖尿病、肥胖症、卒中、代谢综合征、痴呆、阿尔茨海默病或癌症中的任一种。
17.权利要求8所述的方法,其还包括经口施用所选择的组合物。
18.权利要求8所述的方法,其还包括表面施用所选择的组合物。
19.权利要求8所述的方法,其中所选择的组合物是营养组合物、医疗组合物或药物组合物中的任一种。
20.权利要求8所述的方法,其中所选择的组合物是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG),磷脂(PL),半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
21.胶囊剂,其包含至少约50毫克选自以下的任一种:
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)和少于约10%藻类饱和脂肪酸的组合物;
含有按干重计约17%至约90%藻类C16:1n7棕榈油酸(POA)并且基本不含藻类饱和脂肪酸的组合物;
含有按干重计约20%至约97%藻类C20:5n3二十碳五烯酸(EPA)和约17%至约90%藻类C16:1n7棕榈油酸(POA)之共混物的组合物;
含有按总重计至少20%藻类EPA、至少17%藻类POA、约0%至20%藻类饱和脂肪、少于约10%藻类ARA并且基本不含藻类DHA的总藻油组合物;
或者
含有按总重计至少20%藻类EPA、至少17%藻类POA、少于约10%藻类ARA并且基本不含藻类DHA且基本不含藻类饱和脂肪酸的总藻油组合物。
22.权利要求21所述的胶囊剂,其中所述胶囊剂是营养胶囊剂、医疗胶囊剂或药物胶囊剂中的任一种。
23.权利要求21所述的胶囊剂,其还包含抗氧化剂。
24.用于在人中减轻慢性炎症、肥胖症相关体重以及饱腹感的方法,所述方法包括每天经口施用至少一颗胶囊剂,持续至少30天的治疗期,所述胶囊剂的至少约25%的胶囊剂容积包含组合物,所述组合物还含有按干重计约90%棕榈油酸、少于约0.5%饱和脂肪酸、少于约2%花生四烯酸、基本不含二十二碳六烯酸并且含有少于约10%二十碳五烯酸,其中所述组合物是乙酯(EE),单酰甘油、二酰甘油或三酰甘油(MAG、DAG、TAG),磷脂(PL),半乳糖脂(GL),游离脂肪酸(FFA)或硫代异鼠李糖二酰甘油(SQDG)的形式。
25.权利要求24所述的方法,其还包括使升高的慢性炎症标志、升高的肥胖症相关体重标志或升高的饱腹感标志降低。
26.权利要求25所述的方法,其中所述升高的肥胖症相关体重标志为胰岛素水平。
27.权利要求25所述的方法,其中所述升高的饱腹感标志为瘦素水平。
28.权利要求25所述的方法,其中所述升高的慢性炎症标志为IL6。
29.权利要求25所述的方法,其中所述标志是血糖水平。
30.权利要求25所述的方法,其还包括减小腰围。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361800114P | 2013-03-15 | 2013-03-15 | |
US201361800029P | 2013-03-15 | 2013-03-15 | |
US61/800,029 | 2013-03-15 | ||
US61/800,114 | 2013-03-15 | ||
US14/025,772 US9445619B2 (en) | 2013-03-15 | 2013-09-12 | Compositions and methods for utilization of algal compounds |
US14/025,772 | 2013-09-12 | ||
PCT/US2014/025012 WO2014151113A1 (en) | 2013-03-15 | 2014-03-12 | Compositions and methods for utilization of algal compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105209034A true CN105209034A (zh) | 2015-12-30 |
Family
ID=51527995
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480015962.2A Pending CN105102598A (zh) | 2013-03-15 | 2014-03-12 | 藻类油组合物 |
CN201480024225.9A Pending CN105263896A (zh) | 2013-03-15 | 2014-03-12 | 游离脂肪酸向乙酯的转化 |
CN201480022992.6A Pending CN105209034A (zh) | 2013-03-15 | 2014-03-12 | 用于利用藻类化合物的组合物和方法 |
CN201480013299.2A Pending CN105121623A (zh) | 2013-03-15 | 2014-03-18 | 具有改善的生长和生产的叶绿素缺乏型藻细胞 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480015962.2A Pending CN105102598A (zh) | 2013-03-15 | 2014-03-12 | 藻类油组合物 |
CN201480024225.9A Pending CN105263896A (zh) | 2013-03-15 | 2014-03-12 | 游离脂肪酸向乙酯的转化 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480013299.2A Pending CN105121623A (zh) | 2013-03-15 | 2014-03-18 | 具有改善的生长和生产的叶绿素缺乏型藻细胞 |
Country Status (9)
Country | Link |
---|---|
US (6) | US20140275596A1 (zh) |
EP (2) | EP2968244A4 (zh) |
CN (4) | CN105102598A (zh) |
AU (1) | AU2014232150A1 (zh) |
CA (2) | CA2905846A1 (zh) |
HK (1) | HK1220683A1 (zh) |
IL (1) | IL240339A0 (zh) |
MX (1) | MX2015012321A (zh) |
WO (4) | WO2014151113A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9445619B2 (en) | 2013-03-15 | 2016-09-20 | Aurora Algae, Inc. | Compositions and methods for utilization of algal compounds |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101942B2 (en) | 2009-06-16 | 2015-08-11 | Aurora Algae, Inc. | Clarification of suspensions |
US9982272B2 (en) | 2012-12-06 | 2018-05-29 | Synthetic Genomics, Inc. | Algal mutants having a locked-in high light acclimated phenotype |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9266973B2 (en) | 2013-03-15 | 2016-02-23 | Aurora Algae, Inc. | Systems and methods for utilizing and recovering chitosan to process biological material |
US9919016B2 (en) * | 2015-02-10 | 2018-03-20 | Bilal Qizilbash | Product and method of deploying kale derivatives for anti-cancer effects |
CN107287252B (zh) | 2016-04-01 | 2020-07-10 | 中国科学院青岛生物能源与过程研究所 | 一种ω-7脂肪酸合成物及培养黄丝藻生产该合成物的方法与应用 |
US11446348B2 (en) | 2017-12-30 | 2022-09-20 | Bilal Qizilbash | Vegetable powders, methods for manufacturing vegetable powders, and kits thereof |
GB2612927B (en) * | 2018-12-06 | 2023-10-04 | FutureFeed Pty Ltd | Asparagopsis oil composition |
US20230010722A1 (en) * | 2019-10-17 | 2023-01-12 | The Regents Of The University Of California | Biologically-derived fatty acids and polymers |
EP4068951A4 (en) * | 2019-12-05 | 2023-11-22 | Vaxa Technologies Ltd. | NUTRITIONAL SUPPLEMENT FOR ANIMAL AND AQUACULTURE DIET AND METHOD FOR MANUFACTURING SAME |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120225941A1 (en) * | 2011-03-03 | 2012-09-06 | Tersus Pharmaceuticals, LLC | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE |
US20130046020A1 (en) * | 2011-02-11 | 2013-02-21 | E I Du Pont De Nemours And Company | Eicosapentaenoic acid concentrate |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1271516A (en) | 1968-08-30 | 1972-04-19 | British Petroleum Co | Method of separating carboxylic acids or esters thereof |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
WO1994024984A2 (en) * | 1993-04-30 | 1994-11-10 | Winget Rodner R | Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto |
WO2001076588A1 (en) * | 2000-04-06 | 2001-10-18 | Coastside Research | Method to inhibit lipoxygenase and cancer cell proliferation |
JPWO2002077105A1 (ja) | 2001-03-22 | 2004-07-15 | 富士化学工業株式会社 | 安定なアスタキサンチン含有粉体組成物及びその製造方法 |
WO2003015494A2 (en) * | 2001-08-21 | 2003-02-27 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
CA2656311C (en) * | 2006-07-05 | 2016-06-21 | Photonz Corporation Limited | Ultra pure epa and polar lipids produced in largely heterotrophic culture |
WO2009073816A1 (en) | 2007-12-04 | 2009-06-11 | The Ohio State University Research Foundation | Optimization of biofuel production |
US20090311367A1 (en) | 2008-06-17 | 2009-12-17 | Perry Stephen C | Dietary Supplement |
WO2010027505A2 (en) * | 2008-09-05 | 2010-03-11 | Doron Eisenstadt | Decreasing rubisco content of algae and cyanobacteria cultivated in high carbon dioxide |
US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
US20100130608A1 (en) * | 2008-10-01 | 2010-05-27 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
US9187778B2 (en) | 2009-05-04 | 2015-11-17 | Aurora Algae, Inc. | Efficient light harvesting |
US20110072713A1 (en) * | 2009-09-30 | 2011-03-31 | Daniel Fleischer | Processing Lipids |
WO2011097276A1 (en) * | 2010-02-02 | 2011-08-11 | Martek Biosciences Corporation | Methods and compositions for treating arthritis with docosahexaenoic acid |
CA2793695A1 (en) * | 2010-04-06 | 2011-10-13 | Heliae Development, Llc | Selective extraction of proteins from freshwater algae |
US8603094B2 (en) * | 2010-07-26 | 2013-12-10 | Spinal Usa, Inc. | Minimally invasive surgical tower access devices and related methods |
DE112011103527T5 (de) * | 2010-10-21 | 2013-10-17 | Basf Plant Science Company Gmbh | Neue Fettsäure-Desaturasen, -Elongasen, -Elongations-Komponenten und Anwendungen davon |
US20120213713A1 (en) * | 2011-02-18 | 2012-08-23 | Chifu Huang | Compositions of omega fatty acids for the prevention and treatment of dental caries resulting from oral infections |
US8569530B2 (en) * | 2011-04-01 | 2013-10-29 | Aurora Algae, Inc. | Conversion of saponifiable lipids into fatty esters |
CN104011218A (zh) * | 2011-07-21 | 2014-08-27 | 帝斯曼知识产权资产管理有限公司 | 富含多不饱和脂肪酸的微生物油 |
US9200236B2 (en) | 2011-11-17 | 2015-12-01 | Heliae Development, Llc | Omega 7 rich compositions and methods of isolating omega 7 fatty acids |
US20140275596A1 (en) | 2013-03-15 | 2014-09-18 | Aurora Algae, Inc. | Algal omega 7 and algal omega 3 blend compositions |
-
2013
- 2013-09-12 US US14/025,756 patent/US20140275596A1/en not_active Abandoned
- 2013-09-12 US US14/025,740 patent/US20140275613A1/en not_active Abandoned
- 2013-09-12 US US14/025,762 patent/US20140275483A1/en not_active Abandoned
- 2013-09-12 US US14/025,772 patent/US9445619B2/en active Active
- 2013-09-12 US US14/025,766 patent/US20140274922A1/en not_active Abandoned
-
2014
- 2014-03-12 WO PCT/US2014/025012 patent/WO2014151113A1/en active Application Filing
- 2014-03-12 CN CN201480015962.2A patent/CN105102598A/zh active Pending
- 2014-03-12 CA CA2905846A patent/CA2905846A1/en not_active Abandoned
- 2014-03-12 CA CA2906532A patent/CA2906532A1/en not_active Abandoned
- 2014-03-12 EP EP14767703.3A patent/EP2968244A4/en not_active Withdrawn
- 2014-03-12 CN CN201480024225.9A patent/CN105263896A/zh active Pending
- 2014-03-12 WO PCT/US2014/025019 patent/WO2014151116A1/en active Application Filing
- 2014-03-12 EP EP14769076.2A patent/EP2970817A1/en not_active Withdrawn
- 2014-03-12 CN CN201480022992.6A patent/CN105209034A/zh active Pending
- 2014-03-12 WO PCT/US2014/025007 patent/WO2014151110A1/en active Application Filing
- 2014-03-18 AU AU2014232150A patent/AU2014232150A1/en not_active Abandoned
- 2014-03-18 US US14/218,855 patent/US20140273113A1/en not_active Abandoned
- 2014-03-18 MX MX2015012321A patent/MX2015012321A/es unknown
- 2014-03-18 WO PCT/US2014/031127 patent/WO2014146133A2/en active Application Filing
- 2014-03-18 CN CN201480013299.2A patent/CN105121623A/zh active Pending
-
2015
- 2015-08-04 IL IL240339A patent/IL240339A0/en unknown
-
2016
- 2016-07-20 HK HK16108661.3A patent/HK1220683A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130046020A1 (en) * | 2011-02-11 | 2013-02-21 | E I Du Pont De Nemours And Company | Eicosapentaenoic acid concentrate |
US20120225941A1 (en) * | 2011-03-03 | 2012-09-06 | Tersus Pharmaceuticals, LLC | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9445619B2 (en) | 2013-03-15 | 2016-09-20 | Aurora Algae, Inc. | Compositions and methods for utilization of algal compounds |
Also Published As
Publication number | Publication date |
---|---|
WO2014151113A1 (en) | 2014-09-25 |
US20140274922A1 (en) | 2014-09-18 |
WO2014146133A3 (en) | 2014-11-06 |
CN105263896A (zh) | 2016-01-20 |
MX2015012321A (es) | 2015-12-16 |
CN105121623A (zh) | 2015-12-02 |
US20140273113A1 (en) | 2014-09-18 |
WO2014151110A1 (en) | 2014-09-25 |
US9445619B2 (en) | 2016-09-20 |
CN105102598A (zh) | 2015-11-25 |
EP2970817A1 (en) | 2016-01-20 |
AU2014232150A1 (en) | 2015-08-20 |
CA2906532A1 (en) | 2014-09-25 |
HK1220683A1 (zh) | 2017-05-12 |
EP2968244A4 (en) | 2016-10-26 |
WO2014146133A2 (en) | 2014-09-18 |
CA2905846A1 (en) | 2014-09-25 |
US20140275596A1 (en) | 2014-09-18 |
US20140275483A1 (en) | 2014-09-18 |
EP2968244A1 (en) | 2016-01-20 |
IL240339A0 (en) | 2015-09-24 |
US20140271706A1 (en) | 2014-09-18 |
US20140275613A1 (en) | 2014-09-18 |
WO2014151116A1 (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105209034A (zh) | 用于利用藻类化合物的组合物和方法 | |
TWI393536B (zh) | 脂質改良劑及包含脂質改良劑之組成物 | |
US7163960B2 (en) | Treatment and prevention of inflammatory disorders | |
Baker et al. | A review of the functional effects of pine nut oil, pinolenic acid and its derivative eicosatrienoic acid and their potential health benefits | |
US10314871B2 (en) | Isolation of Omega-7 fatty acid ethyl esters from natural oils | |
WO2004093869A1 (en) | Novel dietary compositions to reduce inflammation | |
Borges et al. | Polyunsaturated omega-3 fatty acids and systemic lupus erythematosus: what do we know? | |
CN113287659A (zh) | 一种功能结构油及其制备方法和应用 | |
EP2682116B1 (en) | Metabolic syndrome ameliorating agent | |
Popović et al. | Effects of n–3 supplementation on plasma and liver Phospholipid fatty acids profile in aged Wistar rats | |
EP2845490A1 (en) | Fat composition for improved body fat distribution | |
JP4634065B2 (ja) | アディポネクチン低下抑制剤 | |
WO2020248710A1 (zh) | 一种油脂组合物及其制备方法 | |
WO2011067666A1 (en) | Processes to generate compositions of enriched fatty acids | |
KR100684641B1 (ko) | 유지 조성물, 이를 함유하는 식품 및 건강보조식품 | |
Naveen et al. | Metabolomics of dietary fatty acids: Implications on life style diseases | |
JP2007262014A (ja) | アディポネクチン分泌増加剤 | |
Ötleş et al. | Structured lipids intended for infant nutrition | |
Desai et al. | Health Perspective of Nutraceutical Fatty Acids;(Omega‐3 and Omega‐6 Fatty Acids) | |
Krga et al. | WALNUTS CONSUMPTION MODULATES ENDOGENOUS METABOLIC CONVERSION TOWARDS LONG-CHAIN FATTY ACIDS AND AFFECTS INDIVIDUAL FATTY ACID CONTENT IN PLASMA AND LIVER OF FRUCTOSE-FED RATS | |
JP2022150493A (ja) | 血中中鎖脂肪酸濃度の上昇方法、血中中鎖脂肪酸濃度上昇剤、医薬組成物、食品組成物 | |
JP2020152706A (ja) | 長鎖モノエン脂肪酸(lc−mufa)を有効成分とする腸内細菌叢改善剤 | |
WO2024076288A1 (en) | Oil composition comprising caproic acid residues, unsaturated fatty acid residues and saturated fatty acid residues | |
JP2010241832A (ja) | アディポネクチン低下抑制剤 | |
Choudhury et al. | Exploring the Role of Omega-6/Omega-3 Ratio in Disease Management: Insights from Dietary Impact and Molecular Docking Analyses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151230 |